Post-COVID-19 Pulmonary Fibrosis: Facts—Challenges and Futures: A Narrative Review

Mohammadi A, Balan I, Yadav S, et al. Post-COVID-19 pulmonary fibrosis. Cureus. 2022;14(3):e22770.

Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–32.

Mylvaganam RJ, Bailey JI, Sznajder JI, et al. Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. Eur Respir Rev. 2021;30: 210194.

Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601–15.

Lee JH, Yim JJ, Park J. Pulmonary function and chest computed tomography abnormalities 6–12 months after recovery from COVID-19: a systematic review and meta-analysis. Respir Res. 2022;23(1):233. https://doi.org/10.1186/s12931-022-02163-x. (Published 2022 Sep 6).

d’Ettorre G, Gentilini Cacciola E, Santinelli L, et al. Covid-19 sequelae in working age patients: a systematic review. J Med Virol. 2022;94(3):858–68. https://doi.org/10.1002/jmv.27399.

Mongelli A, Barbi V, Gottardi Zamperla M, et al. Evidence for Biological Age Acceleration and Telomere Shortening in COVID-19 Survivors. Int J Mol Sci. 2021;22(11):6151. https://doi.org/10.3390/ijms22116151. (Published 2021 Jun 7).

Rai DK, Sharma P, Kumar R. Post covid 19 pulmonary fibrosis. Is it real threat? Indian J Tuberc. 2021;68(3):330–3. https://doi.org/10.1016/j.ijtb.2020.11.003.

Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4: e2128568.

Wu C, Chen X, Cai Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. China JAMA Intern Med. 2020;180(7):934–43.

Liu X, Zhou H, Zhou Y. Risk factors associated with disease severity and length of hospital stay in COVID-19 patients. J Infect. 2020;81(1):e95–7.

Tanni SE, Fabro AT, de Albuquerque A, Machado Ferreira EV, Verrastro CGY, Sawamura MVY, et al. Pulmonary fibrosis secondary to COVID-19: a narrative review. Expet Rev Respir Med. 2021;15:791–803.

Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, et al. A Review of Persistent Post-COVID Syndrome (PPCS). Clin Rev Allergy Immunol. 2021;20:1–9.

Esendağli D. Post-COVID syndrome: pulmonary complications. Turk J Med Sci. 2021;51:3359–71.

Bellan M, Soddu D, Balbo PE, et al. Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. JAMA Netw Open. 2021;4: e2036142.

Abdallah SJ, Voduc N, Corrales-Medina VF, et al. Pulmonary function and functional capacity four months after COVID-19. Ann Am Thorac Soc. 2021;18:1912–7.

Vianello, et al. Pulmonary fibrosis in COVID-19 survivors. Clin Chem Lab Med. 2022;60(3):307–16.

Vasarmidi E, Tsitoura E, Spandidos DA, Tzanakis N, Antoniou KM. Pulmonary fibrosis in the aftermath of the COVID-19 era. Exp Ther Med. 2020;20:2557–60.

Burnham EL, Janssen WJ, Riches DWH, et al. The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. Eur Respir J. 2014;43:276–85.

Pelosi P, Rocco PR. Effects of mechanical ventilation on the extracellular matrix. Intensive Care Med. 2008;34:631–9.

Leng L, Cao R, Ma J, et al. Pathological features of COVID-19-associated lung injury: a preliminary proteomics report based on clinical samples. Signal Transduct Target Ther. 2020;5:240. https://doi.org/10.1038/s41392-020-00355-9.

Gentile F, Aimo A, Forfori F, et al. COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead. Eur J Prev Cardiol. 2020;27:1442–6. https://doi.org/10.1177/2047487320932695.

John AE. COVID-19 and pulmonary fibrosis: a potential role for lung epithelial cells and fibroblasts. Immunol Rev. 2021;302:228–40.

George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020;75:1009–16.

Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology. 2021;27:328–37.

Solomon JJ, Heyman B, Ko JP, et al. CT of postacute lung complications of COVID-19. Radiology. 2021;301: 211396.

Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021. https://doi.org/10.1016/S2213-2600(21)00174-0. (published online ahead of print, 2021 May 5).

Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, et al. Six-month follow- up chest CT findings after severe COVID-19 pneumonia. Radiology. 2021;299(1):E177–86. https://doi.org/10.1148/radiol.2021203153.

Alarcón-Rodríguez J, Fernández-Velilla M, Ureña-Vacas A, et al. Radiological management and follow-up of post-COVID-19 patients. Radiologia. 2021;63:258.

Mandal S, Barnett J, Brill SE, et al. “Long-COVID”: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76:396–8.

McGroder CF, Zhang D, Choudhury MA, Salvatore MM, D’Souza BM, Hoffman EA, et al. Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leukocyte telomere length. Thorax. 2021. https://doi.org/10.1136/thoraxjnl-2021-217031. (published online ahead of print, 2021 Apr 29).

D’Cruz R, Waller M, Perrin F, et al. Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia. ERJ Open Res. 2021;7:00655–2020.

Baldi BG, Tanni SE. Pulmonary fibrosis and follow-up of COVID-19 survivors: an urgent need for clarification. J Bras Pneumol. 2021;47(4): e20210213.

Arnold DT, Donald C, Lyon M, Hamilton FW, Morley AJ, Attwood M, et al. Krebs von den Lungen 6 (KL-6) as a marker for disease severity and persistent radiological abnormalities following COVID-19 infection at 12 weeks. PLoS One. 2021;16(4): e0249607. https://doi.org/10.1371/journal.pone.0249607.

Ko UW, Cho EJ, Oh HB, Koo HJ, Do KH, Song JW. Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease. PLoS One. 2020;15: e0244114. https://doi.org/10.1371/journal.pone.0244114.

Peng DH, Luo Y, Huang LJ, et al. Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019. Clin Chim Acta. 2021;517:48–53. https://doi.org/10.1016/j.cca.2021.02.012.

Inoue Y, Kaner RJ, Guiot J, et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases wth a progressive phenotype. Chest. 2020;158:646–59. https://doi.org/10.1016/j.chest.2020.03.037.

George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8:807–15.

Al-kuraishy HM, Batiha GE-S, Faidah H, Al-Gareeb AI, Saad HM, Simal-Gandara J. Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals. Inflammopharmacology. 2022;30:2017–26.

Yoon HY, Park S, Kim DS, Song JW. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. Respir Res. 2018;19:203.

Kerget B, CIL G, Araz O, Alper F, Akgun M. When and how important is anti-fibrotic therapy in the postCOVID-19 period? Bratisl Med J. 2022;123(9):653–8.

Vadász I, Husain-Syed F, Dorfmüller P, et al. Severe organising pneumonia following COVID-19. Thorax. 2021;76:201–4.

Kory P, Kanne JP. SARS-CoV-2 organising pneumonia: “Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?” BMJ Open Respir Res. 2020;7: e000724.

Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383:958–68.

Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. https://doi.org/10.1136/bmj.n136.

Chaudhary S, Natt B, Bime C, Knox KS, Glassberg MK. Antifibrotics in COVID-19 lung disease: let us stay focused. Front Med (Lausanne). 2020;7:539. https://doi.org/10.3389/fmed.2020.00539.

Tanvir M, Wagay I, Nisar S, Ahmed RN, Maqbool M, Kareem O, Muzaffer U. 2022 Early intervention with anti-fibrotic pirfenidone is effective than corticosteroids in preventing pulmonary fibrosis in severe COVID pneumonia patients. Curr Med Res Pract. 2022;12(2):53. https://doi.org/10.4103/cmrp.cmrp_110_21.

Reina-Gutiérrez S, Torres-Costoso A, Martínez-Vizcaíno V, de Arenas-Arroyo SN, Fernández-Rodríguez R, Pozuelo-Carrascosa DP. Effectiveness of pulmonary rehabilitation in interstitial lung disease, including coronavirus diseases: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2021;102:1989-97.e3. https://doi.org/10.1016/j.apmr.2021.03.035.

Goodwin VA, Allan L, Bethel A, et al. Rehabilitation to enable recovery from COVID-19: a rapid systematic review. Physiotherapy. 2021;111:4–22. https://doi.org/10.1016/j.physio.2021.01.007.

Egan JJ. Follow-up and nonpharmacological management of the idiopathic pulmonary fibrosis patient. Eur Respir Rev. 2011;20:114–7. https://doi.org/10.1183/09059180.00001811.

Duong-Quy S, Huynh-Truong-Anh D, Nguyen-Thi-Kim T, Nguyen-Quang T, Nguyen-Chi T, Nguyen-Thi-Y N, Duong-Thi-Thanh V, Ngo C, Craig T. The use of therapeutic plasma exchange in the treatment of a pregnant woman with COVID-19 induced acute respiratory distress syndrome. Pulmonary Therapy. 2022;8(2):233–40.

Duong-Quy S, Huynh-Truong-Anh D, Le-Thi-Hong N, Le-Van T, Le-Thi-Kim S, Nguyen-Quang T, Nguyen-Thi-Kim T, Nguyen-Phuong N, Nguyen-Chi T, Nguyen-Van T, Duong-Thi-Thanh V. Acute respiratory distress syndrome associated with multisystem inflammatory syndrome in a child with Covid-19 and diabetic ketoacidosis: a case report. Pulm Ther. 2022;24:1.